Psychedelics – News and Features

Researchers are a step closer to uncovering why it is so difficult for people to withdraw from some antidepressant drugs.

In this interview, David E. Olson discusses the potential commercial, clinical and scientific implications of non-hallucinogenic psychedelic compounds.

A compound with a similar structure to the psychedelic drug ibogaine, but lacking its toxic and hallucinogenic effects, has been shown to reverse the effects of stress in mice.

To learn more about psychedelic-assisted psychotherapy, the advantages it offers and some of the conditions it could help to treat, Technology Networks spoke with Dr Reid Robison, chief medical officer of Novamind, a mental health company specialized in psychedelic medicine.

We examine three studies that pushed the limits of what experimental scientists can consider ethical in the wake of the Deep Time experiment's conclusion.

A breakthrough trial suggests that MDMA-assisted therapy is both safe and effective for people with post-traumatic stress disorder (PTSD).

A new technology developed by researchers at the University of California Davis promises to fast-track the development of compounds that could exploit psychedelics’ therapeutic action without hallucinogenic side effects.

At the British Neuroscience Association’s 2021 Festival of Neuroscience, a session was devoted to the discussion of new research working towards understanding ketamine’s mechanism of action and its potential use as a treatment for alcohol use disorder.

University of Maryland School of Medicine (UMSOM) researchers have shown that psilocybin—the active chemical in “magic mushrooms”— still works its antidepressant-like actions, at least in mice, even when the psychedelic experience is blocked.

A new trial has directly compared the antidepressant effects of the compound psilocybin with a classical selective serotonin reuptake inhibitor (SSRI) antidepressant, showing the two are matched in their mood-altering potential.